Actively Recruiting
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Led by Tianjin Medical University Second Hospital · Updated on 2024-12-18
300
Participants Needed
1
Research Sites
130 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main purpose of this study is to explore the feasibility of selecting treatment plans based on genomic variations guided by MTB in patients with advanced refractory solid tumors.
CONDITIONS
Official Title
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with recurrent or metastatic malignant solid tumors confirmed by histology or cytology
- Eastern Cooperative Oncology Group (ECOG) performance score between 0 and 4 (3-4 only if tumor burden present)
- Failed, unable to tolerate, or refused standard treatment
- Have at least one measurable tumor lesion meeting RECIST 1.1 criteria
- Expected survival of 3 months or longer
- Age 18 years or older
- Available tumor tissue blocks or sufficient cancer cells from chest or ascites (at least 200 ml), excised metastatic lymph nodes, or peripheral blood sample for genetic testing
- Understand and voluntarily agree to participate and sign informed consent form
You will not qualify if you...
- Currently participating or have actively undergone other clinical trials for treatment
- Serious or uncontrolled medical conditions such as uncontrolled diabetes, chronic kidney or lung disease, active infection, or mental/social conditions limiting study compliance
- Pregnant or breastfeeding women, or patients with fertility who have not used appropriate pregnancy prevention methods
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tianjin Medical Unversity Second Hospital
Tianjin, Tianjin Municipality, China, 300211
Actively Recruiting
Research Team
H
Haitao Wang, Ph.D
CONTACT
J
Jinhuan Wang, Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
9
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here